KDM3B Antibody

What is KDM3B and what is its biological significance?

KDM3B (also known as JMJD1B, 5qNCA, C5orf7, and NET22) is a lysine-specific demethylase that belongs to the alpha-ketoglutarate-dependent hydroxylase superfamily . The protein has a molecular weight of approximately 191.6 kilodaltons and functions primarily as a histone H3 demethylase that specifically catalyzes the demethylation of H3K9me1/2 .

KDM3B plays critical roles in multiple biological processes. Knockout studies in mice have demonstrated that KDM3B is required for normal spermatogenesis and male sexual behaviors . Additionally, KDM3B has been implicated in cell growth and transformation, functioning as a potential tumor suppressor in myeloid leukemia, myelodysplasia, and breast cancer, while potentially promoting acute promyelocytic leukemia . Recent research has also identified KDM3B as an important biomarker for various cancers including acute lymphoblastic leukemia, breast cancer, colorectal cancer, and lung non-small cell carcinoma .

What expression patterns does KDM3B exhibit in mammalian tissues?

KDM3B protein expression has been well-characterized in multiple tissue types, with particularly notable expression in reproductive organs. In mouse testes, KDM3B protein is highly expressed in:

• Leydig cells

• Sertoli cells

• Spermatogonia

• Spermatocytes at different differentiation stages

Additionally, KDM3B protein has been observed in the epithelial cells of the:

• Caput epididymis

• Prostate

• Seminal vesicle

The protein shows expression patterns similar to its family member KDM3A in germ cells, with both being highly expressed in pachytene cells . This widespread expression across reproductive tissues aligns with its functional importance in reproduction, as evidenced by knockout studies showing reduced fertility in KDM3B-deficient mice.

What are the common applications of KDM3B antibodies in research?

KDM3B antibodies serve multiple critical applications in epigenetic and cancer research. Based on validation data, the most common applications include:

When selecting a KDM3B antibody, researchers should consider the specific application requirements and choose antibodies validated for their target species and experimental technique. Most commercially available antibodies demonstrate reactivity with human, mouse, and rat samples .

How should KDM3B antibodies be stored and handled for optimal performance?

Proper storage and handling of KDM3B antibodies are essential for maintaining antibody integrity and experimental reproducibility. The following guidelines should be observed:

• Storage temperature: Most KDM3B antibodies should be stored at -20°C for long-term stability . Avoid repeated freeze-thaw cycles by aliquoting antibodies upon receipt.

• Buffer conditions: Typical storage buffers include PBS, pH 7.2, with 0.1% sodium azide as a preservative . When working with cell cultures, remember that sodium azide is toxic to living cells, so appropriate washing steps should be implemented.

• Working dilutions: Prepare working dilutions immediately before use and discard any unused diluted antibody to prevent degradation.

• Handling precautions:

  • Minimize exposure to light for conjugated antibodies

  • Keep antibodies on ice during experimental procedures

  • Avoid contamination by using sterile techniques

  • Follow supplier recommendations for specific antibodies

• Stability considerations: Most antibodies maintain activity for at least 12 months when stored properly, but performance should be validated before critical experiments, particularly with older antibody stocks.

A common methodological approach to extend antibody shelf-life is to add a carrier protein (such as BSA) to diluted antibody solutions to prevent adsorption to tube walls and increase stability during storage.

How do knockout models inform our understanding of KDM3B function?

Knockout models have been instrumental in elucidating the physiological functions of KDM3B. Studies with KDM3B knockout (Kdm3bKO) mice have revealed several critical phenotypes:

Reproductive phenotypes in male Kdm3bKO mice:

• 68% reduction in the number of pups produced when bred with wild-type females

• 44% fewer mature sperm in cauda epididymides

• Significantly reduced sperm motility

• Increased latencies to mount, intromit and ejaculate

• Decreased number of mounts and intromissions

• Loss of interest in female odors

Other phenotypes:

• Restricted postnatal somatic growth

• Decreased levels of insulin growth factor binding protein-3 (IGFBP-3) expression

• Significantly decreased IGF-1 stability in blood circulation

• Complete infertility in female mice due to irregular estrous cycles, decreased ovulation, fertilization, and uterine decidual response

Methodologically, these knockout studies employed careful phenotypic characterization through breeding tests, hormone assays, behavioral analyses, and molecular assessments. When designing similar studies, researchers should consider:

• The importance of both male and female reproductive assessment

• Behavioral evaluation alongside physiological parameters

• Molecular profiling to identify downstream effects

• Comparative studies with related enzymes (e.g., KDM3A) to identify unique and redundant functions

Notably, KDM3B knockout resulted in less severe spermatogenesis defects than KDM3A knockout, suggesting differential roles despite similar expression patterns in the testis .

How can researchers validate KDM3B antibody specificity?

Validating antibody specificity is critical for ensuring reliable experimental results. For KDM3B antibodies, a comprehensive validation strategy should include:

• Western blot analysis with appropriate controls:

  • Positive controls from tissues/cells known to express KDM3B (e.g., testis, HEK-293, HeLa)

  • Negative controls using KDM3B knockout tissues/cells

  • Molecular weight verification (expected ~192 kDa; sometimes observed at 85 kDa)

  • Competitive blocking with immunizing peptide

• Immunofluorescence pattern assessment:

  • Subcellular localization consistent with nuclear histone demethylase

  • Co-localization with other nuclear markers

  • Comparison with mRNA expression patterns

• Cross-reactivity testing:

  • Evaluation against closely related family members (e.g., KDM3A)

  • Species cross-reactivity assessment if using in multiple model systems

• Genetic validation approaches:

  • siRNA/shRNA knockdown followed by antibody staining

  • CRISPR/Cas9 knockout validation

  • Overexpression systems with tagged constructs

• Mass spectrometry validation:

  • Immunoprecipitation followed by mass spectrometry analysis

  • Confirmation of peptide sequences unique to KDM3B

A methodological example from the literature involves the use of antibodies against Kdm3b (2621S, Cell signaling), along with histone H3 (H3) (ab1791, Abcam), H3K9me1 (ab9045, Abcam), H3K9me2 (07-441, Upstate), and H3K9me3 (07-442, Upstate) for validation of specificity and functional analysis .

What techniques are effective for studying KDM3B enzymatic activity?

Assessing the histone demethylase activity of KDM3B requires specialized approaches. The following methods have proven effective:

• In vitro demethylase assays:

  • Recombinant KDM3B protein incubated with synthetic H3K9me1/2 peptide substrates

  • Detection of demethylation using:

    • Mass spectrometry

    • Antibodies specific for methylation states

    • Fluorescence-based assays

• Cellular demethylation assays:

  • Overexpression of wild-type vs. catalytically inactive KDM3B mutants

  • Western blot analysis of H3K9me1/2 levels

  • Immunofluorescence staining of H3K9 methylation states

  • ChIP-seq to identify genomic regions with altered H3K9 methylation

• Oxygen consumption measurements:

  • As an α-ketoglutarate-dependent dioxygenase, KDM3B activity can be monitored through oxygen consumption

  • Clark-type electrode or fluorescence-based oxygen sensors can track reaction progress

• HDAC inhibitor controls:

  • HDAC inhibitors can be used to distinguish between direct demethylation and indirect effects

• Formaldehyde release assay:

  • Measures formaldehyde produced during demethylation reaction

  • Can be coupled with colorimetric detection methods

When studying KDM3B enzymatic activity, researchers should note that unlike KDM3A knockout, KDM3B knockout did not show obvious global changes in H3K9me1 and H3K9me2 levels in testes, suggesting that KDM3B might act more specifically at certain gene loci rather than globally affecting histone methylation .

What molecular mechanisms underlie KDM3B's role in cancer?

KDM3B has complex, context-dependent roles in cancer pathogenesis, functioning as both a tumor suppressor and oncogene depending on the cancer type. The molecular mechanisms include:

• Tumor suppressor functions:

  • Potential tumor suppressor role in myeloid leukemia, myelodysplasia, and breast cancer

  • Likely mediated through regulation of cell cycle genes and apoptotic pathways

  • May involve direct demethylation of H3K9 at tumor suppressor gene promoters

• Oncogenic functions:

  • May promote acute promyelocytic leukemia

  • Functions as a biomarker in multiple cancer types:

    • Acute lymphoblastic leukemia

    • Breast cancer

    • Colorectal cancer

    • Lung non-small cell carcinoma

• Epigenetic regulation mechanisms:

  • Alteration of chromatin accessibility at key genomic loci

  • Modulation of transcription factor binding through H3K9 demethylation

  • Potential interaction with other epigenetic modifiers

• Growth signaling pathways:

  • Connection to IGF signaling pathway, as evidenced by decreased IGFBP-3 expression in knockout mice

  • Potential cross-talk with hormone signaling (estrogen, androgen receptors)

Research approaches to study these mechanisms include:

• ChIP-seq to identify direct KDM3B target genes in cancer cells

• RNA-seq after KDM3B modulation to identify transcriptional effects

• Protein interaction studies to map KDM3B-containing complexes

• Animal models with tissue-specific KDM3B deletion or overexpression

• Correlation studies between KDM3B expression/activity and clinical outcomes

Understanding these molecular mechanisms is essential for exploring KDM3B as a potential therapeutic target in certain cancers or as a diagnostic/prognostic biomarker.

How do I troubleshoot inconsistent KDM3B detection in Western blot experiments?

Inconsistent KDM3B detection in Western blots can arise from multiple factors. The following troubleshooting guide addresses common issues:

• Protein extraction challenges:

  • KDM3B is a large nuclear protein (192 kDa) , requiring efficient nuclear extraction

  • Solution: Use specialized nuclear extraction buffers with DNase treatment

  • Include protease inhibitor cocktails to prevent degradation

• Transfer inefficiency:

  • Large proteins transfer poorly from gel to membrane

  • Solution: Extend transfer time or use specialized protocols for large proteins

  • Consider wet transfer methods with lower methanol concentrations

  • Use PVDF membranes rather than nitrocellulose for better binding of large proteins

• Antibody selection issues:

  • Different antibodies may recognize different epitopes or isoforms

  • Solution: KDM3B antibodies may detect bands at 192 kDa (full-length) or 85 kDa (potential isoform/fragment)

  • Test multiple validated antibodies (e.g., GeneTex, Aviva Systems Biology, Proteintech)

• Optimization approaches:

  • Titrate antibody concentrations (recommended range: 1:2000-1:12000 for WB)

  • Optimize blocking conditions and incubation times

  • Consider signal enhancement systems for low-abundance detection

• Validation controls:

  • Include positive controls (HEK-293, HeLa, HepG2 cells, human placenta tissue)

  • When possible, include knockout/knockdown samples as negative controls

  • Use recombinant KDM3B protein as a standard

For specific detection issues, some labs report success using antibodies targeted to specific regions of KDM3B, such as C-terminal antibodies or those targeting the N-terminal region .

Comparative Research Questions

Understanding the genomic targets of KDM3B requires specialized chromatin immunoprecipitation approaches. The following methods are particularly effective:

• ChIP-seq (Chromatin Immunoprecipitation followed by sequencing):

  • Requires highly specific KDM3B antibodies suitable for ChIP applications

  • Typically uses formaldehyde crosslinking to preserve protein-DNA interactions

  • Sonication optimization is critical for proper chromatin fragmentation

  • Advanced data analysis to identify enriched regions and correlate with gene expression

• CUT&RUN or CUT&Tag:

  • Alternative to traditional ChIP with improved signal-to-noise ratio

  • Particularly useful for factors with weak or transient DNA interactions

  • Requires fewer cells than traditional ChIP

  • Combines antibody targeting with in situ enzymatic DNA cleavage

• Sequential ChIP (ChIP-reChIP):

  • Identifies genomic regions co-occupied by KDM3B and other factors

  • Useful for studying KDM3B interaction with transcription factors or other chromatin modifiers

• ChIP-MS:

  • Combines ChIP with mass spectrometry to identify proteins associated with KDM3B at chromatin

  • Helps define the composition of KDM3B-containing complexes

• Genome-wide correlation studies:

  • Integration of KDM3B binding data with:

    • Histone modification patterns (particularly H3K9me1/2)

    • Transcription factor binding profiles

    • Gene expression data

    • Chromatin accessibility (ATAC-seq, DNase-seq)

When designing these experiments, researchers should consider using both N-terminal and C-terminal targeting antibodies to account for potential protein interactions that might mask epitopes. Multiple commercially available antibodies have been validated for research use, including those from Cell Signaling (2621S), which has been successfully used in published research .

How does KDM3B contribute to reproductive system development and function?

KDM3B plays crucial roles in both male and female reproductive systems, with distinct contributions to development and function:

Male reproductive system:

• Expression in multiple testicular cell types (Leydig cells, Sertoli cells, spermatogonia, spermatocytes)

• Expression in accessory glands (epididymis, prostate, seminal vesicle)

• Essential for normal spermatogenesis, with knockout resulting in:

  • 44% reduction in sperm numbers

  • Significantly reduced sperm motility

  • Compromised male sexual behaviors

Female reproductive system:

• Essential for female fertility, with knockout causing:

  • Irregular estrous cycles

  • Decreased ovulation

  • Impaired fertilization

  • Reduced uterine decidual response

Molecular mechanisms:

• In female tissues, KDM3B knockout leads to increased H3K9me1, H3K9me2, and H3K9me3 levels

• In male tissues, no obvious global changes in these histone marks were observed, suggesting locus-specific effects

• Appears to regulate sex hormones, with knockout males showing:

  • Normal testosterone levels but

  • Markedly reduced 17β-estradiol levels, which affects sperm maturation and sexual behaviors

These findings highlight KDM3B's context-dependent epigenetic regulation across the reproductive system. The most effective research approach combines:

• Tissue-specific conditional knockout models

• Hormone profiling

• Behavioral assessment

• Molecular characterization of histone modification changes

• Developmental timeline analysis of KDM3B expression and function

What are the considerations when choosing between polyclonal and monoclonal KDM3B antibodies?

The choice between polyclonal and monoclonal KDM3B antibodies should be guided by experimental requirements. Each antibody type offers distinct advantages:

Polyclonal KDM3B Antibodies:

Monoclonal KDM3B Antibodies:

Methodological recommendations:

• For critical experiments, validate results with both antibody types

• Consider region-specific antibodies (C-terminal, N-terminal) as protein interactions may mask certain epitopes

• For novel applications, pilot with polyclonal before investing in monoclonal development

• For reproducibility across long-term studies, monoclonals offer advantages

When selecting any KDM3B antibody, review validation data to ensure compatibility with your specific application, species, and experimental conditions .

How can RNA-seq and ChIP-seq be integrated to understand KDM3B function?

Integrating RNA-seq and ChIP-seq provides powerful insights into KDM3B's functional mechanisms by connecting its genomic binding sites with transcriptional outcomes. A comprehensive integration approach includes:

• Experimental design considerations:

  • Perform both assays in the same cellular context and conditions

  • Include appropriate controls (input DNA, IgG controls for ChIP; RNA controls)

  • Consider time-course experiments to capture dynamic regulation

  • Include KDM3B depletion/overexpression conditions

• Data analysis pipeline:

  • Identify KDM3B binding sites from ChIP-seq

  • Map binding sites to genomic features (promoters, enhancers, gene bodies)

  • Correlate binding with H3K9me1/2 demethylation patterns

  • Identify differentially expressed genes from RNA-seq

  • Integrate to determine direct KDM3B targets (genes both bound and regulated)

• Functional classification:

  • Perform pathway analysis on direct targets

  • Identify transcription factor motifs enriched at binding sites

  • Correlate with other epigenetic marks (H3K4me3, H3K27ac)

• Validation approaches:

  • Targeted ChIP-qPCR at selected loci

  • RT-qPCR validation of expression changes

  • Reporter assays for functional validation

  • CRISPR-mediated deletion of KDM3B binding sites

In published studies, researchers have employed quantitative RT-PCR (QPCR) to validate gene expression changes, using gene-specific primer pairs and universal mouse probe sets, with results normalized to endogenous 18S RNA . This approach can complement genome-wide studies by providing focused validation of key targets.

The integration of these methodologies has revealed that while KDM3A knockout causes global H3K9me1/2 changes, KDM3B knockout appears to have more locus-specific effects, highlighting the importance of integrative analyses to capture the full spectrum of KDM3B function .

What emerging technologies will advance KDM3B functional studies?

Several cutting-edge technologies are poised to significantly advance our understanding of KDM3B function:

• Single-cell multi-omics approaches:

  • Single-cell RNA-seq combined with single-cell ATAC-seq to correlate KDM3B activity with gene expression and chromatin accessibility at the single-cell level

  • Single-cell CUT&Tag for KDM3B and histone modifications to map cell-specific epigenetic landscapes

  • These approaches will help resolve cell-type-specific functions, particularly important given KDM3B's expression across multiple cell types in tissues like testes

• CRISPR-based epigenome editing:

  • Targeted recruitment of catalytically active or inactive KDM3B to specific genomic loci

  • Precise modification of H3K9 methylation status at individual genes

  • Allows causal testing of KDM3B's role at specific targets without altering global expression

• Proximity labeling technologies:

  • BioID or APEX2 fusions with KDM3B to identify context-specific protein interaction networks

  • Helps identify cell-type-specific cofactors that may explain differential functions in various tissues

• Cryo-EM structural studies:

  • High-resolution structures of KDM3B alone and in complex with nucleosomes

  • Structure-guided development of specific inhibitors or activators

  • Better understanding of how KDM3B recognizes its substrate

• Tissue-specific conditional knockout models:

  • Cell-type-specific deletion to dissect functions in complex tissues

  • Inducible systems to separate developmental from acute adult functions

  • These models will help address the tissue-specific roles observed between KDM3A and KDM3B

The implementation of these technologies will help resolve outstanding questions about KDM3B's differential roles in male versus female reproduction, its context-dependent functions in cancer, and the specificity of its genomic targets across different cell types.

How might therapeutic targeting of KDM3B be developed for cancer treatment?

The development of KDM3B-targeted therapeutics represents an emerging area with potential applications in cancer treatment, based on its context-dependent roles in tumor suppression and oncogenesis . Strategic approaches include:

• Inhibitor development strategies:

  • Structure-based design targeting the JmjC catalytic domain

  • Allosteric inhibitors that prevent protein-protein interactions

  • Degrader technologies (PROTACs) to induce KDM3B degradation in specific contexts

  • Consideration of cancer-specific differential targeting based on KDM3B's dual roles

• Cancer-specific targeting approaches:

  • Activation strategies for cancers where KDM3B functions as a tumor suppressor (myeloid leukemia, myelodysplasia, breast cancer)

  • Inhibition approaches for contexts where KDM3B promotes cancer (acute promyelocytic leukemia)

  • Biomarker development for patient stratification in:

    • Acute lymphoblastic leukemia

    • Breast cancer

    • Colorectal cancer

    • Lung non-small cell carcinoma

• Combination therapy considerations:

  • Synergistic targeting with other epigenetic modifiers

  • Integration with conventional chemotherapy

  • Potential for synthetic lethality approaches

• Delivery system development:

  • Nanoparticle formulations for tumor-specific delivery

  • Antibody-drug conjugates targeting cancer-specific surface markers

  • Cell-penetrating peptide conjugates for intracellular delivery

• Preclinical evaluation framework:

  • Patient-derived xenograft models

  • Genetically engineered mouse models with tissue-specific alterations

  • Organoid systems for drug screening

The complexity of KDM3B's biological roles necessitates careful consideration of context-specific functions when developing therapeutic approaches. Molecular profiling of individual tumors will likely be essential to determine whether KDM3B activation or inhibition would be beneficial in specific cancer contexts.